Longevity Weekly Pulse: Key Takeaways From ASCO Conference

The report summarizes key takeaways from the 2026 ASCO conference, focusing on oncology advancements including Merck's lung cancer clinical data and Innovent Bio's strategic partnership with Pfizer.

Key Takeaways

• 1.Oncology remains a critical therapeutic area for pharmaceutical innovation and revenue growth within the Longevity theme.
• 2.Merck's Sac-TMT drug demonstrated promise in front-line lung cancer, though additional data is needed to assess broad commercial impact.
• 3.China's biotech innovation is gaining significant international validation, exemplified by the $650 million Pfizer-Innovent Bio collaboration.

Table of Contents

• Thoughts of the week
• Merck & Co: Sac-TMT drug shows promising data in subtype of lung cancer patients
• Roche: Further details from the failed persevERA study for giredestrant in breast cancer
• Innovent Bio: IBI363 provides encouraging lung cancer data
• PD-L1/VEGF approach in lung cancer remains in focus
• Charts of the week
• Appendix

Document Preview

Page 1 of 1

Subscribe for full accessStart Free Trial